SCHEMBL734204

SCHEMBL734204

OCCCCc1c[nH]c2ccccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 2/20 0.61
CYP3A4 P08684 4/20 0.61
HTR2A P28223 3/20 0.61
CYP1A2 P05177 3/20 0.61
CYP2D6 P10635 3/20 0.61
HTR2C P28335 2/20 0.61
MPO P05164 1/20 0.61
CYP2A6 P11509 1/20 0.61
NFKB1 P19838 1/20 0.61
HTR1D P28221 1/20 0.61
HTR1B P28222 1/20 0.61
HTR7 P34969 1/20 0.61
CTSK P43235 1/20 0.61
HTR6 P50406 1/20 0.61
CYP2A13 Q16696 1/20 0.61
TAAR1 Q96RJ0 1/20 0.61
HTR1A P08908 3/20 0.59
PMP22 Q01453 1/20 0.59
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29441817 1.00 SLC6A4 (0.61) SLC6A4CYP3A4HTR2ACYP1A2CYP2D6
SCHEMBL1518985 0.98 SLC6A4 (0.59) SLC6A4CYP3A4HTR2ACYP1A2CYP2D6
SCHEMBL1518996 0.98 SLC6A4 (0.59) SLC6A4CYP3A4HTR2ACYP1A2CYP2D6
SCHEMBL1518971 0.98 SLC6A4 (0.59) SLC6A4CYP3A4HTR2ACYP1A2CYP2D6
SCHEMBL1293186 0.98 SLC6A4 (0.59) SLC6A4CYP3A4HTR2ACYP1A2CYP2D6
SCHEMBL29391207 0.98 SLC6A4 (0.59) SLC6A4CYP3A4HTR2ACYP1A2CYP2D6
SCHEMBL28649099 0.98 SLC6A4 (0.59) SLC6A4CYP3A4HTR2ACYP1A2CYP2D6
SCHEMBL1518978 0.98 SLC6A4 (0.59) SLC6A4CYP3A4HTR2ACYP1A2CYP2D6
SCHEMBL1519001 0.98 SLC6A4 (0.59) SLC6A4CYP3A4HTR2ACYP1A2CYP2D6
SCHEMBL31366243 0.95 SLC6A4 (0.63) SLC6A4CYP3A4HTR2ACYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114195695-B Preparation method of 3- (4-hydroxybutyl) -1H-indole compound 上海应用技术大学 2023-02-10 CN claimed
CN-114195695-A Preparation method of 3- (4-hydroxybutyl) -1H-indole compound 上海应用技术大学 2022-03-18 CN claimed
CN-114195695-B Preparation method of 3- (4-hydroxybutyl) -1H-indole compound 上海应用技术大学 2023-02-10 CN disclosed
CN-114195695-B Preparation method of 3- (4-hydroxybutyl) -1H-indole compound 上海应用技术大学 2023-02-10 CN disclosed
CN-114195695-B Preparation method of 3- (4-hydroxybutyl) -1H-indole compound 上海应用技术大学 2023-02-10 CN disclosed
CN-114195695-A Preparation method of 3- (4-hydroxybutyl) -1H-indole compound 上海应用技术大学 2022-03-18 CN disclosed
CN-114195695-A Preparation method of 3- (4-hydroxybutyl) -1H-indole compound 上海应用技术大学 2022-03-18 CN disclosed
CN-114195695-A Preparation method of 3- (4-hydroxybutyl) -1H-indole compound 上海应用技术大学 2022-03-18 CN disclosed
EP-3027607-B1 SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2020-08-26 EP disclosed
US-10316025-B2 Substituted piperazine compounds and methods of use and use thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2019-06-11 US disclosed
CN-108456198-A The preparation method of vilazodone or its hydrochloride 江苏豪森药业集团有限公司 2018-08-28 CN disclosed
US-5807871-A PSYCHOLOGICAL DISORDERS, ALZHEIMER OR PARKINSON DISEASE H. LUNDBECK A/S (DK) 1998-09-15 US disclosed
EP-0593511-B1 PIPERIDINE DERIVATES HAVING ANXIOLYTIC EFFECT LUNDBECK & CO AS H (DK) 1998-09-02 EP disclosed
EP-0859004-A1 Piperidine derivatives having anxiolytic effect H. LUNDBECK A/S (DK) 1998-08-19 EP disclosed
EP-0853085-A1 Piperidine derivatives having anxiolytic effect H. LUNDBECK A/S (DK) 1998-07-15 EP disclosed
US-5665725-A Piperidine derivatives having anxiolytic effect Lundbeck, H. (DK) 1997-09-09 US disclosed
EP-0593511-A1 PIPERIDINE DERIVATES HAVING ANXIOLYTIC EFFECT H. LUNDBECK A/S (DK) 1994-04-27 EP disclosed
WO-1992022554-A1 PIPERIDINE DERIVATES HAVING ANXIOLYTIC EFFECT H. LUNDBECK A/S (DK) 1992-12-23 WO disclosed
EP-0518805-A1 Piperidine derivatives H. LUNDBECK A/S (DK) 1992-12-16 EP disclosed
EP-0007399-B1 INDOLYLALKYL AMINES, PHARMACEUTICAL PREPARATIONS CONTAINING THEM AND PROCESS FOR THEIR MANUFACTURE MERCK PATENT GmbH (DE) 1982-01-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10316025-B2 Substituted piperazine compounds and methods of use and use thereof HTR5A, HTR2C, TPH1 SLC6A4 14/4885CYP3A4 378/4885HTR2A 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.